Tag:
PLX4032
Latest Headlines
Latest Headlines
BMS, Roche join forces and drugs on combo melanoma program
If you want to attack an aggressive killer like metastatic melanoma, it's best to target it from as many angles as possible. That's the approach that Roche is taking with its promising late-stage
Roche cancer programs angle for a starring role at ASCO
Roche set the stage for its upcoming review of new mid- and late-stage data on vemurafenib--its closely watched experimental treatment for skin cancer licensed in from Plexxikon-at the annual ASCO
Roche, Plexxikon melanoma drug extends patients' lives
Roche and partner Plexxikon have reported a rare success in the challenging field of melanoma. Closely-watched drug PLX4032 extended the lives of subjects with metastatic melanoma in a Phase III
PLX4032 inspires fierce debate over cancer trial designs
Plexxikon's PLX4032 has been the subject of tremendous buzz after the biotech unveiled startling efficacy data from a small trial of lethal melanoma cases. Now its pivotal study is triggering a loud
Roche melanoma drug registers striking results
An experimental personalized cancer therapy from Roche and Plexxikon registered striking results in a recent clinical study, shrinking the tumors in a majority of metastatic melanoma patients who
The roller coaster ride of melanoma drug development
This week, the New York Times is tracing the Phase I testing of a novel melanoma drug being developed by Plexxikon and Roche. The paper says to chronicle the three years of PLX4032 testing "is to
